Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099421 | 0.92 | KDM4E (0.35) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14099514 | 0.92 | KDM4E (0.35) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14099420 | 0.91 | SIGMAR1 (0.40) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL14099253 | 0.90 | KDM4E (0.36) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL14099377 | 0.89 | SIGMAR1 (0.41) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL17468436 | 0.86 | SIGMAR1 (0.43) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL11947025 | 0.85 | ADORA2A (0.34) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL24702723 | 0.85 | SIGMAR1 (0.42) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4887864 | 0.85 | SIGMAR1 (0.42) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL30343585 | 0.85 | SIGMAR1 (0.42) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956011-A1 | AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | Idemitsu Kosan Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070132372-A1 | AMINE BASED COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070132372-A1 | AMINE BASED COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070132372-A1 | AMINE BASED COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | KCNH2, SLC7A5, KCNH3 | SIGMAR1 2031/4885KDM4E 1016/4885ALDH1A1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.